Catalyst Calendar

Thu, Jul 30, 2026

1 updates

6:30 AM

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Mitapivat (PYRUKYND ® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025 Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026 sNDA

Trial Start • Phase 3Trial initiation Sun, Nov 1, 2026agios.com

Tue, Jul 21, 2026

1 updates

AGIO

7:00 AM

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell disease Safety and tolerability of tebapivat were consistent with prior sickle cell

Trial Results • Phase 2Phase 2 topline results Tue, Jul 21, 2026agios.com